LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

Inclusion Criteria: * Fully understand and voluntarily sign informed consent. * Male, aged 18 to 75 years old. * Expected survival \> 6 months. * CRPC patients: Prostate cancer is still progressing after continuous androgen deprivation therapy. Including, castrate levels of serum testosterone (\<50ng/dl or \<1.7nmol/L); or prostate specific antigen (PSA) increased more than 50% at intervals of one week or three consecutive times, and PSA\>1 ug/L; or imaging scans revealed two or more new lesions or enlargement of soft tissue lesions that met the criteria for evaluating solid tumor response. * CRPC patients received abiraterone or chemotherapy for 3 months or more, and were ineffective or progressive (PSA continued to rise for 3 months, or bone scan/whole-body MRI/PET-CT showed local recurrence or new metastasis). * Immunohistochemical staining of repetitive biopsy tissues showed the expression of PSMA in tumor cells was more than 50%. * ECOG score \<2. * Hgb \> 10 g/dl. * PLT \> 100×109/L. * ANC \> 1.5×109/L. Exclusion Criteria: Subjects who meet any of the following exclusion criteria will be excluded * Prior treatment with any immunotherapy, including CART therapy, tumor vaccine therapy, radium-223, checkpoint inhibitors. * Prior treatment with any PSMA targeting therapy. * Subjects with severe mental disorders. * Subjects with severe cardiovascular diseases: a, New York Heart Association (NYHA) stage III or IV congestive heart failure; b, history of myocardial infarction or coronary artery bypass grafting (CABG) within 6 months; c, clinical significance of ventricular arrhythmia, or history of unexplained syncope, non-vasovagal or dehydration; d, history of severe non-ischemic cardiomyopathy; e, the left ventricular ejection fraction (LVEF \< 55%) was decreased by echocardiography or MUGA scan (within 8 weeks before PBMC collection), and abnormal interventricular septal thickness and atrioventricular size associated with myocardial amyloidosis. * Patients with ongoing or active infection. * Aspartate aminotransferase or Alanine aminotransferase \>2.5\*ULN; CK\>1.5\*ULN; CK-MB\>1.5\*ULN; TnT\>1.5\*ULN. * Total bilirubin \>1.5\*ULN. * Partial prothrombin time or activated partial thromboplastin time or international standardized ratio \> 1.5\*ULN without anticoagulant treatment. * History of participation in other clinical studies within 3 months or treatment with any gene therapy product. * Intolerant or allergic to cyclophosphamide or fludarabine. * Subjects not appropriate to participate in this clinical study judged by investigators.